August 6, 2021 -- Twist Bioscience reported revenue increases for the third quarter of fiscal 2021, which ended June 30.
The company said revenue increased to $35 million for the quarter compared to $21.2 million for the same period of the 2020 fiscal year.
Quarterly highlights cited by the company included its support for the Engineering Biology Research Consortium and its statement of ethics in Engineering Biology Research. Twist also noted its acquisition of iGenomX and launch of the Twist Library Preparation Enzymatic Fragmentation Kit 2.0.
Twist said it aims to increase revenue guidance, which is now expected to be in the range of $129 million to $132 million.